Patents Assigned to Xencor, Inc.
  • ENGINEERED IMMUNOGLOBULINS WITH EXTENDED IN VIVO HALF-LIFE
    Publication number: 20140161790
    Abstract: The present application relates to immunoglobulin compositions with improved half-life, and their application, particularly for therapeutic purposes.
    Type: Application
    Filed: November 19, 2013
    Publication date: June 12, 2014
    Applicant: Xencor, Inc.
    Inventors: John Desjarlais, Gregory Alan Lazar
  • Optimized Fc Variants
    Patent number: 8735547
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Grant
    Filed: April 25, 2013
    Date of Patent: May 27, 2014
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • Optimized fc variants and methods for their generation
    Patent number: 8734791
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Grant
    Filed: February 27, 2012
    Date of Patent: May 27, 2014
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John R. Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • Fc variants having increased affinity for fcyrllc
    Patent number: 8735545
    Abstract: The present invention relates to Fc variants having increased affinity for Fc?RIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Grant
    Filed: June 19, 2007
    Date of Patent: May 27, 2014
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • Optimized Antibodies That Target CD19
    Publication number: 20140112916
    Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fcg?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.
    Type: Application
    Filed: September 10, 2013
    Publication date: April 24, 2014
    Applicant: Xencor, Inc.
    Inventors: Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik Weiking Pong, John O. Richards, Eugene Alexander Zhukovsky
  • NOVEL CTLA4-IG IMMUNOADHESINS
    Publication number: 20140112924
    Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
    Type: Application
    Filed: December 27, 2013
    Publication date: April 24, 2014
    Applicant: XENCOR, INC.
    Inventors: GREGORY A. LAZAR, MATTHEW J. BERNETT
  • Optimized Antibodies That Target CD19
    Publication number: 20140086906
    Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fcg?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.
    Type: Application
    Filed: August 5, 2013
    Publication date: March 27, 2014
    Applicant: Xencor, Inc.
    Inventors: Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik Weiking Pong, John O. Richards, Eugene Alexander Zhukovsky
  • OPTIMIZED Fc VARIANTS
    Publication number: 20140073768
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Application
    Filed: November 12, 2013
    Publication date: March 13, 2014
    Applicant: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • FC VARIANTS THAT EXTEND ANTIBODY HALF-LIFE
    Publication number: 20140056879
    Abstract: The invention relates generally to compositions and methods for altering the serum half-life in vivo of an antibody.
    Type: Application
    Filed: August 22, 2013
    Publication date: February 27, 2014
    Applicant: XENCOR, INC.
    Inventor: GREGORY A. LAZAR
  • Antibodies with modified isoelectric points
    Patent number: 8637641
    Abstract: The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. increased serum half-life in vivo.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: January 28, 2014
    Assignee: Xencor, Inc.
    Inventors: Bassil I. Dahiyat, Gregory A. Lazar, Matthew J. Bernett
  • CTLA4-Ig immunoadhesins
    Patent number: 8629113
    Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
    Type: Grant
    Filed: December 10, 2012
    Date of Patent: January 14, 2014
    Assignee: Xencor, Inc.
    Inventors: Gregory A. Lazar, Matthew J. Bernett
  • METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
    Publication number: 20130315910
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: November 29, 2012
    Publication date: November 28, 2013
    Applicant: XENCOR, INC.
    Inventor: Xencor, Inc.
  • Optimized Fc Variants
    Publication number: 20130302315
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Application
    Filed: June 14, 2013
    Publication date: November 14, 2013
    Applicant: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • Optimized Fc Variants
    Publication number: 20130273043
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Application
    Filed: June 11, 2013
    Publication date: October 17, 2013
    Applicant: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • Anti-CD40 antibodies and methods of inhibiting proliferation of CD40 expressing cells
    Patent number: 8551485
    Abstract: The present invention describes humanized antibodies that target CD40, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.
    Type: Grant
    Filed: January 21, 2009
    Date of Patent: October 8, 2013
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik WeiKing Pong, Eugene Alexander Zhukovsky
  • Optimized Fc Variants
    Publication number: 20130261289
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Application
    Filed: April 25, 2013
    Publication date: October 3, 2013
    Applicant: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • Fc variants that extend antibody half-life
    Patent number: 8546543
    Abstract: The invention relates generally to compositions and methods for altering the serum half-life in vivo of an antibody.
    Type: Grant
    Filed: October 12, 2011
    Date of Patent: October 1, 2013
    Assignee: Xencor, Inc.
    Inventor: Gregory Alan Lazar
  • Optimized Fc Variants and Methods for Their Generation
    Publication number: 20130243762
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Application
    Filed: May 20, 2013
    Publication date: September 19, 2013
    Applicant: XENCOR, INC.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • Optimized antibodies that target CD19
    Patent number: 8524867
    Abstract: Antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcyR or alters effector function as compared to the parent antibody, and methods of using the antibodies.
    Type: Grant
    Filed: August 14, 2007
    Date of Patent: September 3, 2013
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik WeiKing Pong, John O. Richards, Eugene Alexander Zhukovsky
  • Optimized Fc Variants
    Publication number: 20130209445
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Application
    Filed: March 8, 2013
    Publication date: August 15, 2013
    Applicant: Xencor, Inc.
    Inventors: Gregory A. Lazar, Wei Dang, John Desjarais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter